Advertisement

Primärprävention kardiovaskulärer Ereignisse bei Hypertonikern unter besonderer Berücksichtigung des plötzlichen Herztodes

  • J. Wikstrand
Chapter

Zusammenfassung

Der vorliegende Artikel behandelt die Primärprävention des plötzlichen Herztodes bei Hypertonikern sowie die kardiovaskulären und renalen Wirkungen einer sehr langfristigen Behandlung der Hypertonic unter spezieller Berücksichtigung von Metoprolol.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    JNC V (1992) The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). National Institutes of Health. October 30, 1992.Google Scholar
  2. 2.
    Wikstrand J, Berglund G, Tuomilehto J (1991) Beta-blockade in the primary prevention of coronary heart disease in hypertensive patients. Review of present evidence. Circulation (suppl VI): VI93–VI100.Google Scholar
  3. 3.
    Wikstrand J, Kendall M (1992) The role of beta receptor blockade in preventing sudden death. Eur Heart J 13 (suppl D): 111–120.PubMedGoogle Scholar
  4. 4.
    Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Elmfeldt D, Berglund G on behalf of the Advisory Committee (1991) Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 17: 579–588.Google Scholar
  5. 5.
    Kannel WB, Thomas HE (1982) Sudden coronary death: The Framingham Study. In: Green- berg HM, Dwyer EM (eds) Sudden coronary death, vol 382, New York Academy of Sciences, New York, pp 3–20.Google Scholar
  6. 6.
    Green KG (1991) British MRC trial of treatment for mild hypertension - a more favorable interpretation. Am J Hypertens 4: 723–724.PubMedGoogle Scholar
  7. 7.
    Olsson G, Tuomilehto J, Berglund G et al. (1991) Primary prevention of sudden cardiovascular death in hypertensive patients: Mortality results from the MAPHY study. Am J Hypertens 4: 151–158.PubMedGoogle Scholar
  8. 8.
    Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G on behalf of the Advisory Committee. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 259: 1976–1982.Google Scholar
  9. 9.
    Tuomilehto J, Wikstrand J, Olsson G et al. (1989) Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study. Hypertension 13: 773–780.Google Scholar
  10. 10.
    Johannesson M, Wikstrand J, Jonsson B, Berglund G, Tuomilehto J (1933) Cost-effectiveness of antihypertensive treatment. Metoprolol versus thiazide diuretics. Pharmacoeconomics 3: 36–44.CrossRefGoogle Scholar
  11. 11.
    Olsson G, Wikstrand J, Warnold I et al. (1992) Metoprolol induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials. Eur Heart J 13: 28–32.PubMedGoogle Scholar
  12. 12.
    Muller JE, Verrier RL (1996) Triggering of su4den death. Lessons from an earthquake. N Engl I Med 334: 460–461.Google Scholar
  13. 13.
    Ablad B, Bjuro T, Bjorkman J-A, Edstrom T, Olsson G (1991) Role of central nervous beta- adrenoceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone. J Am Coll Cardiol 17(2): 165A.CrossRefGoogle Scholar
  14. 14.
    Skinner JE (1985) Regulation of cardiac vulnerability by the cerebral defense system. J Am Coll Cardiol 5: 88B–94B.PubMedCrossRefGoogle Scholar
  15. 15.
    Parker GW, Michael LH, Hartley CJ, Skinner JE, Entman JE (1990) Central ß-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ Res 66: 259–270.PubMedGoogle Scholar
  16. 16.
    Dimenas E, Kerr D, Macdonald IA (1990) Beta-adrenoceptor blockade and CNS-related subjective symptoms: A randomized, double-blind, placebo-controlled comparison of metoprolol CR/ZOK, atenolol and propranolol LA in healty subjects. J Clin Pharmacol 30 (suppl): S103–S107.PubMedGoogle Scholar
  17. 17.
    SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265: 3255–3264.CrossRefGoogle Scholar
  18. 18.
    Medical Research Council Working Party (1992) Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304: 405–412.CrossRefGoogle Scholar
  19. 19.
    Wikstrand J, Westergren G, Berglund G et al. (1986) Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60–75 years. JAMA 255: 1304–1310.PubMedCrossRefGoogle Scholar
  20. 20.
    Wikstrand J, Trimarco B, Buzzetti G, Ricciardelli B, Luca N de, Volpe M, Condorelli M (1983) Increased cardiac output and lowered peripheral resistance during metoprolol treatment. Acta Med Scand (suppl) 672: 105–110.Google Scholar
  21. 21.
    Hartford M, Wendelhag I, Berglund G, Wallentin I, Ljungman S, Wikstrand J (1988) Cardio-vascular and renal effects of long-term antihypertensive treatment. JAMA 259: 2553–2557.PubMedCrossRefGoogle Scholar
  22. 22.
    Gretzer I, Hjemdahl P (1997) Differential effects of metoprolol and prazosin on the forearm vasculature in primary hypertension. J Hypertens in press.Google Scholar
  23. 23.
    Ljungman S, Wikstrand J, Hartford M, Aurell M, Lindstedt G, Berglund G. Effects of long- term antihypertensive treatment and aging on renal function and albumin excretion in pri-mary hypertension. Accepted in Am J Hypertens.Google Scholar
  24. 24.
    Siewert-Delle A, Ljungman S, Hartford M, Wikstrand J (1995) Effects of intensified blood- pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with ß-blockade. Am J Hypertens 8: 113–123.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • J. Wikstrand

There are no affiliations available

Personalised recommendations